Docrates is the first to launch a new type of alpha radiation therapy in the Nordic region

Alpha radiation is an experimental type of radiotherapy that is being studied as a viable option for treating prostate cancer, the most common cancer in men, in situations where castration-resistant prostate cancer has metastatised and standard forms of therapy are not effective. High-energy alpha radiation is more effective at destroying cancer tissue, and the treatment is also better at targeting micrometastases, compared to beta radiation.

In 2017, Docrates Cancer Center introduced isotope treatments, in other words, radiotherapy, for the treatment of metastatic prostate cancer. Almost 1,500 Docrates patients have already received radiotherapy. According to the latest research*, alpha radiation treatments can achieve good responses in patients with an extensively metastatic cancer or who have had an inadequate response to beta radiation-based isotope therapy. The combination of isotope therapies based on alpha and beta radiation has also shown promising preliminary results.

– We are excited to become the first service provider in the Nordic region to introduce new types of alpha radiation treatments. Our solutions for treating metastatic prostate cancer include hormone therapy and chemotherapy, as well as radiotherapy and isotope therapy.  However, cancer can change and an individual medicine or treatment may lose its effectiveness. Cancer treatment often requires a combination of different treatments, and alpha radiation therapy is a welcome addition to this arsenal, says Juha Kononen, Chief Clinical Director at Docrates Cancer Center.

– We are now on the verge of something new. Alpha radiation is an effective type of particle radiation that can now be used as an individual form of therapy for people with prostate cancer. The research results of the treatments are very promising, says Jukka Kemppainen , Chief Physician in Nuclear Medicine at Docrates Cancer Center.

Docrates Cancer Center uses the latest international research data in the individual treatment of patients with cancer and introduces new diagnostic methods and treatments as soon as they become available.

*Learn more about the study here >

For more information, please contact:
Juha Kononen, Chief Clinical Director
Docrates Cancer Center